Biomarkers in Samples From Young Patients With Neuroblastoma

Children's Oncology Group20 enrolled

Overview

RATIONALE: Studying samples of tissue and bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study studies biomarkers in samples from young patients with neuroblastoma.

OBJECTIVES: Primary * To analyze the expression of ROR1 on the surface of primary neuroblastoma cells. * To investigate the therapeutic potential of anti-ROR1 monoclonal antibodies (mAbs), bispecific antibodies, and immunotoxins in in vitro and in vivo models of neuroblastoma. OUTLINE: Archived bone marrow and tumor tissue samples are analyzed for ROR1 expression by flow cytometry, western blotting, qPCR, and IHC.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Neuroblastoma

Interventions

polymerase chain reactionGENETIC

protein expression analysisGENETIC

western blottingGENETIC

flow cytometryOTHER

Eligibility

Sex: ALLMax age: 120 Years

Medical Language ↔ Plain English

DISEASE CHARACTERISTICS: * Diagnosed with neuroblastoma * With or without N-myc amplification * Primary tumor samples as frozen tissue in liquid nitrogen or -80 degrees C * Bone marrow samples from high-risk patients as peripheral blood mononuclear cells (PBMC) that have been cryopreserved with DMSO as viable cells to be used for flow cytometry or slides of bone marrow that can be used for immunohistochemistry PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * Not specified

Outcomes

Primary Outcomes

ROR1 is expressed on the surface of neuroblastoma cells and constitutes a suitable target for mAb therapy

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.